The Immune-Endocrine-Epigenetics Research Group in the Department of Infection and Immunity investigates how epigenetic processes such as DNA methylation integrate the environment and inherited traits to predispose individuals to diseases. In the context of the FNR funded CORE grant “Age Acceleration and the Life Course (ALAC)” the team is now seeking a dedicated PhD Student.

The IT-X-HD unit is a newly-formed team dedicated to providing IT and data analysis solutions for researchers and principal investigators (PIs) at LIH. By joining our team, you will be involved in projects concerning public health research and various other support activities for our national partners, e.g. the Ministry of Health.   As the .Net Software Developer, you will be: Developing and maintaining IT solutions for the different projects submitted to the unit: epidemiological studies, national registries or any other projects; Working in close collaboration with the IT-X-HD team and the different support and platform teams to implement sustainable solutions; Proposing IT methods and IT solutions to implement team and business needs.

The IT-X-HD unit is a newly-formed team dedicated to providing IT and data analysis solutions for researchers and principal investigators (PIs) at LIH. By joining our team, you will be involved in projects concerning public health research and various other support activities for our national partners, e.g. the Ministry of Health.  As the IT BI Developer, you will be: Providing Ad Hoc reports and data analysis; Developing new or modifying existing data marts, and organizing data in data warehouse; Developing and modifying extraction, transformation and loading procedures (ETL) using SSIS packages; Proposing IT methods and IT solutions to implement team and business needs.

Research Luxembourg, a joint initiative of the main players in Luxembourg's public research sector, is mobilising its knowledge and its human and material resources to help address the challenge of COVID-19.

Immune evasion is a hallmark of cancer progression and represents a major hurdle to the design of effective therapeutic strategies. We recently uncovered a widely conserved mechanism by which resistant tumor cells respond to immune effector cell attack. The ACTIVASION project aims at exploring how this mechanism (i.e. fast remodeling of the tumor cell actin cytoskeleton) alters the structure and the function of the immunological synapse, the cell-cell interaction interface used by immune cells to recognize and kill target cancer cells.

Postdoctoral fellows Amela Jusic, from the LIH Department of Population Health (DoPH), Marie Boudaud and Tomasz Uchanski, from the LIH Department of Infection and Immunity (DII), have been awarded financial support in the framework of the European Commission’s “Marie Sklodowska-Curie Individual Fellowships” funding scheme. The programme will back the scientists’ work on hypertension, receptor-chemokine interactions and Inflammatory Bowel Diseases (IBD).

Transversal Translational Medicine (TTM) at the LIHcreates a translational bridge between fundamental research and the clinic sothat improved/advanced diagnosis, therapy and prevention may help patients inLuxembourg and beyond.  TTM wishes torecruit a Project Manager. The incumbent will be project lead for EATRIS-plusproject (50%) and other TTM research programs (50%). The aim of EATRIS-Plusis to help pooling and exploiting the translational academic capacities of theinfrastructure in omic technologies to enable researchers to better address thescientific and societal challenge of personalized medicine. Additionally, thecoordination office and 13 existing national nodes of the infrastructure willparticipate in implementing joint outreach, training, industry engagement andinternational collaboration activities to further build national capacity,increase users’ trust and strengthen EATRIS and the ERA global scientificleadership.

The ‘Proteomics of Cellular Signaling’ research group of the LIH Quantitative Biology Unit, led by Prof Gunnar Dittmar, has teamed up with Bruker Daltonics, a leading international manufacturer of mass spectrometers, to develop new applications for targeted proteomics on their new flagship mass spectrometer ‘TimsTOF Pro’. The goal of this collaboration, which saw the endowment of one of Bruker’s novel mass spectrometers to the research group, is to develop new targeted techniques to improve the measurement of diagnostic biomarkers for cancer and other diseases.